STOCK TITAN

AstraZeneca (NASDAQ: AZN) reports 1,551,033,389 total voting rights and no treasury shares

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

AstraZeneca PLC reports an updated share capital and voting rights position in line with UK disclosure rules. As at 31 July 2026, the company’s issued share capital with voting rights consists of 1,551,033,389 ordinary shares of US$0.25 each.

No shares are held in Treasury, so the total number of voting rights is also 1,551,033,389. Shareholders may use this figure as the denominator to assess whether they must notify interests or changes in interests under the Financial Conduct Authority’s Disclosure and Transparency Rules.

Positive

  • None.

Negative

  • None.
Total voting rights 1,551,033,389 Total number of voting rights in AstraZeneca PLC as at 31 July 2026
Issued ordinary shares with voting rights 1,551,033,389 Issued share capital of AstraZeneca PLC with voting rights as at 31 July 2026
Par value per ordinary share US$0.25 Nominal value of each ordinary share in the issued share capital
Treasury shares 0 Number of AstraZeneca PLC shares held in Treasury as at 31 July 2026
Total Voting Rights regulatory
"Total Voting Rights The following notification is made in accordance"
The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.
issued share capital financial
"As at 31 July 2026 the issued share capital of AstraZeneca PLC"
Issued share capital is the total value or number of a company's shares that have been created and given to investors, employees or others; think of it as the slices of a cake that have already been cut and distributed. It matters to investors because it determines ownership percentages, potential voting power and how future share sales can dilute existing holdings, affecting share value and control.
Treasury financial
"No shares are held in Treasury. Therefore, the total number"
The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.
Disclosure and Transparency Rules regulatory
"by which they will determine if they are required to notify their interest"
Rules that require companies to provide accurate, timely and complete information about their finances, operations, risks and governance to regulators, investors and the public. They matter to investors because consistent, clear reporting is like a reliable scoreboard: it makes it easier to compare companies, spot problems early, reduce surprises and fraud, and form better expectations about future performance and value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many total voting rights does AstraZeneca (AZN) report as of 31 July 2026?

AstraZeneca (AZN) reports 1,551,033,389 total voting rights as at 31 July 2026. This equals its issued ordinary share capital with voting rights and reflects that no shares are held in Treasury under UK Disclosure and Transparency Rule 5.6.1.

What is the par value of AstraZeneca (AZN) ordinary shares in this filing?

Each AstraZeneca (AZN) ordinary share has a par value of US$0.25. The company states that its issued share capital with voting rights comprises ordinary shares of this nominal value as of 31 July 2026, forming the basis for total voting rights.

Does AstraZeneca (AZN) hold any treasury shares as of 31 July 2026?

AstraZeneca (AZN) reports that it holds no shares in Treasury as of 31 July 2026. As a result, the total number of voting rights is identical to the number of issued ordinary shares with voting rights, 1,551,033,389.

How should AstraZeneca (AZN) shareholders use the total voting rights figure?

Shareholders may use the 1,551,033,389 total voting rights figure as the denominator when calculating whether they must notify their interest, or any change in interest, under the Financial Conduct Authority’s Disclosure and Transparency Rules.

Which regulatory rule governs AstraZeneca’s (AZN) total voting rights disclosure?

The disclosure is made in accordance with the Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1. This rule requires listed companies to update the market on their total voting rights to support shareholder notification calculations.

FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of August 2026 
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Total Voting Rights
 
 
 3 August 2026
 
 
Total Voting Rights
 
 
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 July 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,033,389 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,033,389.
 
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
Matthew Bowden
Company Secretary
AstraZeneca PLC
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 03 August 2026
 
 
By: /s/ Matthew Bowden
 
Name: Matthew Bowden
 
Title: Company Secretary